Your Followed Topics

Top 2 u.s. food and drug administration News Today

#1
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System
#1 out of 2
technology22h ago

Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System

  • ACIST Pro Diagnostic System received U.S. FDA clearance and is launching in the United States to enhance precision in interventional cardiology.
  • Bracco and ACIST say the Pro System builds on automated, real-time contrast delivery to replace manual injections.
  • Prior data cited shows reduced contrast use and lower nephropathy risk with automated contrast delivery.
  • The Pro System was first introduced in Japan in 2025 and later launched in Europe after CE MDR approval in February 2026.
  • Bracco and ACIST position the Pro System as a standard for safe, efficient, precise contrast delivery in cath labs.
  • Executives from Bracco and ACIST Herald the launch as a milestone for precision imaging in the cath lab.
  • ACIST CEO Brad Fox emphasizes efficiency and safety in delivering contrast with ACIST Pro.
  • ACIST Pro is part of Bracco’s broader portfolio in diagnostic imaging and contrast management.
  • The system targets cardiovascular procedures, aiming to improve patient outcomes with better image guidance.
  • The release notes ongoing commitment to innovation in cardiovascular imaging.
Vote 0
0
#2
Key facts: FDA Approves Baxfendy; Citi Keeps 18,000p on AstraZeneca
#2 out of 2100.00%
health3h ago

Key facts: FDA Approves Baxfendy; Citi Keeps 18,000p on AstraZeneca

  • FDA approves Baxfendy for adults with high blood pressure not controlled by two drugs.
  • AstraZeneca bought Baxfendy from CinCor in 2023; Phase III results were positive.
  • Citi maintains an 18,000p target on AstraZeneca amid recent stock moves.
  • Upcoming Phase III readouts may act as near-term catalysts for AstraZeneca.
  • TradingView reports provide a concise overview of Baxfendy’s approval and AZN outlook.
  • AstraZeneca’s Baxfendy history traces to its 2023 Baxfendy acquisition from CinCor.
  • The article notes Baxfendy’s Phase III results were positive.
  • AZN stock activity described as down about 10% last month.
  • The report emphasizes Revenue potential exceeding $5 billion from Baxfendy.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement